argenx SE raises $1.465 billion in stock and notes offering

Ticker: ARGX · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1697862

Sentiment: bullish

Topics: financing, stock-offering, convertible-notes

TL;DR

argenx just closed a massive $1.465B stock & convertible notes offering on 6/21!

AI Summary

On June 21, 2024, argenx SE announced the closing of its previously announced offering of 1,500,000 ordinary shares at a price of $310.00 per share, resulting in gross proceeds of approximately $465 million. The company also announced the closing of its offering of 1.00% convertible senior notes due 2029, raising approximately $1.0 billion in gross proceeds. These offerings were completed on June 21, 2024.

Why It Matters

This significant capital raise provides argenx with substantial funds to advance its pipeline and operations, potentially accelerating drug development and market entry.

Risk Assessment

Risk Level: medium — While the capital raise is positive, the company's success is still tied to the clinical and commercial performance of its drug candidates.

Key Numbers

Key Players & Entities

FAQ

What was the total amount raised by argenx SE in its recent offerings?

argenx SE raised approximately $465 million from the offering of ordinary shares and approximately $1.0 billion from the offering of convertible senior notes, for a total of approximately $1.465 billion.

When did argenx SE close these offerings?

The offerings were closed on June 21, 2024.

What was the price per ordinary share in the stock offering?

The ordinary shares were offered at a price of $310.00 per share.

What is the principal amount and maturity of the convertible senior notes?

The filing mentions the closing of an offering of 1.00% convertible senior notes due 2029, indicating a principal amount was raised and the notes mature in 2029.

What is the purpose of this Form 6-K filing?

This Form 6-K is a report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, providing information about the closing of the offerings.

Filing Stats: 300 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-06-24 06:05:27

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. ARGENX SE Date: June 24, 2024 By: /s/ Hemamalini (Malini) Moorthy Name: Hemamalini (Malini) Moorthy Title: General Counsel

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing